BACKGROUND: Recurrent exacerbation of chronic external otitis represents a special challenge for the attending physician. The goal of our study was to evaluate the effectiveness of novel topical immunomodulators acting through an anti-inflammatory, nonsteroidal mechanism. PATIENTS AND METHODS: In a prospective study, in 33 patients an ear wick containing tacrolimus ointment (Protopic 0.1%) was inserted every 2-3 days. Altogether, the wick was changed three times. Therapeutic outcomes were assessed by reexaminations, video-otoscopy, and a standardized findings sheet. RESULTS: Twenty-eight patients showed significant improvement of clinical symptoms, with 13 of them showing complete healing (follow-up 10-22 months). Relapses (15 cases) were associated with significantly extended symptom-free intervals and reduced numbers of further recurrent episodes. CONCLUSIONS: Because of the safe and successful anti-inflammatory effects, topical immunomodulators represent a new alternative in chronic inflammatory stages of otherwise therapy-resistant external otitis.
BACKGROUND: Recurrent exacerbation of chronic external otitis represents a special challenge for the attending physician. The goal of our study was to evaluate the effectiveness of novel topical immunomodulators acting through an anti-inflammatory, nonsteroidal mechanism. PATIENTS AND METHODS: In a prospective study, in 33 patients an ear wick containing tacrolimus ointment (Protopic 0.1%) was inserted every 2-3 days. Altogether, the wick was changed three times. Therapeutic outcomes were assessed by reexaminations, video-otoscopy, and a standardized findings sheet. RESULTS: Twenty-eight patients showed significant improvement of clinical symptoms, with 13 of them showing complete healing (follow-up 10-22 months). Relapses (15 cases) were associated with significantly extended symptom-free intervals and reduced numbers of further recurrent episodes. CONCLUSIONS: Because of the safe and successful anti-inflammatory effects, topical immunomodulators represent a new alternative in chronic inflammatory stages of otherwise therapy-resistant external otitis.
Authors: Anton Stuetz; Karl Baumann; Maximilian Grassberger; Klaus Wolff; Josef G Meingassner Journal: Int Arch Allergy Immunol Date: 2006-08-22 Impact factor: 2.749
Authors: Peter S Roland; Francis D Pien; Craig C Schultz; Dan C Henry; Peter J Conroy; G Michael Wall; Rekha Garadi; Sheryl J Dupre; Susan L Potts; L Gail Hogg; David W Stroman Journal: Curr Med Res Opin Date: 2004-08 Impact factor: 2.580
Authors: Alan B Fleischer; Mark Ling; Lawrence Eichenfield; Yoichi Satoi; Eileen Jaracz; M Joyce Rico; Rochelle M Maher Journal: J Am Acad Dermatol Date: 2002-10 Impact factor: 11.527
Authors: Susanne Wiegand; Reinhard Berner; Antonius Schneider; Ellen Lundershausen; Andreas Dietz Journal: Dtsch Arztebl Int Date: 2019-03-29 Impact factor: 5.594